首页> 美国卫生研究院文献>Frontiers in Aging Neuroscience >Current Experimental Studies of Gene Therapy in Parkinsons Disease
【2h】

Current Experimental Studies of Gene Therapy in Parkinsons Disease

机译:帕金森氏病基因治疗的最新实验研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Parkinson's disease (PD) was characterized by late-onset, progressive dopamine neuron loss and movement disorders. The progresses of PD affected the neural function and integrity. To date, most researches had largely addressed the dopamine replacement therapies, but the appearance of L-dopa-induced dyskinesia hampered the use of the drug. And the mechanism of PD is so complicated that it's hard to solve the problem by just add drugs. Researchers began to focus on the genetic underpinnings of Parkinson's disease, searching for new method that may affect the neurodegeneration processes in it. In this paper, we reviewed current delivery methods used in gene therapies for PD, we also summarized the primary target of the gene therapy in the treatment of PD, such like neurotrophic factor (for regeneration), the synthesis of neurotransmitter (for prolong the duration of L-dopa), and the potential proteins that might be a target to modulate via gene therapy. Finally, we discussed RNA interference therapies used in Parkinson's disease, it might act as a new class of drug. We mainly focus on the efficiency and tooling features of different gene therapies in the treatment of PD.
机译:帕金森氏病(PD)的特征是迟发性进行性多巴胺神经元丢失和运动障碍。 PD的进展影响神经功能和完整性。迄今为止,大多数研究都主要针对多巴胺替代疗法,但是左旋多巴诱发的运动障碍的出现阻碍了该药的使用。 PD的机制非常复杂,以至于仅添加药物很难解决问题。研究人员开始关注帕金森氏病的遗传基础,寻找可能影响其中神经变性过程的新方法。在本文中,我们回顾了目前用于PD基因疗法的递送方法,我们还总结了基因疗法治疗PD的主要目标,例如神经营养因子(用于再生),神经递质的合成(用于延长持续时间)。左旋多巴)和可能通过基因疗法调控的潜在蛋白质。最后,我们讨论了用于帕金森氏病的RNA干扰疗法,它可能是一类新的药物。我们主要关注不同基因疗法在PD治疗中的效率和工具特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号